FDA Rejects Replimune Melanoma Therapy, Shares Drop

• Jefferies downgraded Replimune to 'Hold' from 'Buy' with a price target cut to $2 from $13, expecting shares to drop over 50% following the FDA rejection
• Replimune's RP1 therapy showed a 34% response rate and 24.8-month median duration of response in the IGNYTE trial, but the FDA deemed the data insufficient for accelerated approval
• The company's cash runway extends only into Q1 2027 and may not cover key clinical milestones, including overall survival analysis from the IGNYTE-3 study expected in 2027

Summary

Key Development:

The FDA has rejected Replimune Group's (NASDAQ:REPL) melanoma therapy RP1, triggering a sharp decline in share value. The biotechnology company sought accelerated approval based on its IGNYTE clinical program targeting advanced melanoma patients who had progressed on prior anti-PD-1 therapy.

Clinical Data:

The study demonstrated a 34% response rate and a median duration of response of 24.8 months, with what Replimune characterized as a favorable safety profile. Despite these results, the FDA deemed the dataset insufficient for approval.

Company Response:

Replimune expressed disagreement with the FDA's decision and cited frustration over limited communication during the review process and the appointment of a new review team during resubmission. Management described the regulatory process as "broken" and announced significant operational consequences, including workforce reductions and scaling back of U.S. manufacturing operations. The company stated it will not pursue further development of RP1 without timely accelerated approval.

Analyst Reaction:

Jefferies downgraded Replimune from 'Buy' to 'Hold' and slashed its price target from $13 to $2, projecting a share price decline exceeding 50%. The firm noted uncertainty around future regulatory strategies and clinical plans.

Financial Outlook:

Replimune's cash runway extends into Q1 2027, but analysts warned this may be insufficient to support the company through key clinical milestones, including a potential overall survival analysis from the ongoing IGNYTE-3 study expected in 2027.

Market Implication:

This rejection represents a significant setback for Replimune and raises broader concerns about FDA regulatory predictability for biotechnology companies pursuing accelerated approval pathways.